Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study

Sally F. Barrington, MSc, MD1; Elizabeth H. Phillips, MBBS2; Nicholas Counsell, MSc2; Barry Hancock, MD3; Ruth Pettengell, PhD4; Peter Johnson, MD5; William Townsend, MD6; Dominic Culligan, MD7; Bilyana Popova, MSc2; Laura Clifton-Hadley, PhD7; Andrew McMillan, PhD8; Peter Hoskin, PhD9,10; Michael J. O’Doherty, MA, MSc, MD11; Tim Illidge, MD, PhD12; and John Radford, MD10

PURPOSE Accurate stratification of patients is an important goal in Hodgkin lymphoma (HL), but the role of pretreatment clinical risk stratification in the context of positron emission tomography (PET)–adapted treatment is unclear. We performed a subsidiary analysis of the RAPID trial to assess the prognostic value of pretreatment risk factors and PET score in determining outcomes.

PATIENTS AND METHODS Patients with stage IA to IIA HL and no mediastinal bulk underwent PET assessment after three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine; 143 PET-positive patients (PET score, 3 to 5) received a fourth doxorubicin, bleomycin, vinblastine, and dacarbazine cycle and involved-field radiotherapy, and 419 patients in complete metabolic remission were randomly assigned to receive involved-field radiotherapy (n = 208) or no additional treatment (n = 211). Cox regression was used to investigate the association between PET score and pretreatment risk factors with HL-specific event-free survival (EFS).

RESULTS High PET score was associated with inferior EFS, before (P < .001) and after adjustment (P = .01) for baseline risk stratification. Only patients with a postchemotherapy PET score of 5 (uptake ≥ three times maximum liver uptake) had an increased risk of progression or HL-related death (hazard ratio, 9.4 v score of 3; 95% CI, 2.8 to 31.3 and hazard ratio, 6.7 v score of 4; 95% CI, 1.4 to 31.7). Patients with a PET score of 5 also had inferior progression-free and overall survival. There was no association between European Organisation for Research and Treatment of Cancer or German Hodgkin Study Group risk group and EFS, before or after adjusting for PET score (all P > .4).

CONCLUSION In RAPID, a positive PET scan did not carry uniform prognostic weight; only a PET score of 5 was associated with inferior outcomes. This suggests that in future trials involving patients without B symptoms or mediastinal bulk, a score of 5 rather than a positive PET result should be used to guide treatment escalation in early-stage HL.

INTRODUCTION The goal of Hodgkin lymphoma (HL) treatment is to optimize patient outcomes by maximizing cure while minimizing toxicity. Cure rates for early-stage HL are high, but treatment toxicity reduces long-term survival and confers significant morbidity.1,2 Risk-adapted treatment strategies can potentially address this but are reliant on accurate risk stratification of patients to facilitate individualized treatment approaches. The German Hodgkin Study Group (GHSG) and the European Organisation for Research and Treatment of Cancer (EORTC) have developed clinical prognostic scores for early-stage HL that are frequently used to risk stratify patients for treatment selection,3,5 but it is unclear whether these scores have sufficient specificity to predict outcomes with modern combined-modality treatment.6

Over the past decade, early response to treatment assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) has emerged as a powerful prognostic indicator in HL.7,8 PET-guided approaches have been evaluated in trials9–13 and successfully implemented in clinical practice,14 as one of the first applications of personalized medicine. The introduction of the 5-point scale for PET reporting helped to standardize image interpretation15 and allowed the threshold used to define a positive PET scan to be adapted according to the research question.16 In trials involving patients with HL, a positive
PET scan has been defined as either FDG uptake greater than the normal mediastinum (PET score, 3, 4, or 5) or equal to or greater than the liver uptake (score, 4 or 5), partly dependent on whether the study intervention involves treatment escalation or de-escalation. Little is known about the predictive value of individual PET scores, and it remains unclear whether all PET-positive or -negative patients derive equal benefit from PET-adapted approaches.

The randomized H10 study demonstrated that patients with early-stage HL with a positive PET scan after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) benefit from treatment intensification. Patients with positive PET scans had a progression-free survival (PFS) advantage when switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escBEACOPP), compared with continuing ABVD, although they experienced greater toxicity. PET positivity in H10 was defined by International Harmonization Project (IHP) criteria (broadly equivalent to PET scores of 3, 4, or 5), and it is unknown whether all patients with a PET score of 3 or higher derive equal benefit from treatment escalation. We performed this subsidiary analysis of the United Kingdom (UK) National Cancer Research Institute (NCRI) RAPID (Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages I/IIA Hodgkin’s Disease) study, in which all PET-positive patients continued ABVD, to explore whether a subset of PET-positive patients with early-stage HL could be adequately treated with ABVD and radiotherapy. Our aim was to investigate the associations of PET score after three cycles of ABVD, pretreatment risk factors, and clinical prognostic scores with patient outcomes.

**PATIENTS AND METHODS**

**Study Design**
The RAPID trial was one of the first to use a PET-adapted treatment approach in early-stage HL. The primary objective of this phase III noninferiority study was to investigate whether PET response could be used to omit radiotherapy in selected patients and reduce late toxicity. The trial design and randomization procedures have been published. In brief, patients with newly diagnosed, histologically confirmed stage IA or IIA HL were eligible if age 16 to 75 years and without mediastinal bulk disease.
TABLE 1. Baseline Demographic and Clinical Characteristics (N = 562)  

| Characteristic                  | PET Negative | IFRT (n = 208) | NFT (n = 211) | PET Positive (n = 143) |
|---------------------------------|--------------|----------------|---------------|-----------------------|
| **Age, years**                  |              |                |               |                       |
| Median                          | 34           | 34             | 36            |                       |
| Range                           | 16-74        | 16-75          | 18-75         |                       |
| < 50                            | 160 (76.9)   | 166 (78.7)     | 103 (72.0)    |                       |
| ≥ 50                            | 48 (23.1)    | 45 (21.3)      | 40 (28.0)     |                       |
| **Sex**                         |              |                |               |                       |
| Female                          | 106 (51.0)   | 104 (49.3)     | 49 (34.3)     |                       |
| Male                            | 102 (49.0)   | 107 (50.7)     | 94 (65.7)     |                       |
| **Stage**                       |              |                |               |                       |
| IA                              | 69 (33.2)    | 70 (33.2)      | 46 (32.2)     |                       |
| IIA                             | 139 (66.8)   | 141 (66.8)     | 97 (67.8)     |                       |
| ESR ≥ 50 (n = 468)              | 20 (11.8)    | 22 (12.1)      | 19 (16.4)     |                       |
| Nonmediastinal bulk present     | 2 (1.0)      | 1 (0.5)        | 3 (2.1)       |                       |
| Extracranial disease present    | 0            | 1 (0.5)        | 0             |                       |
| **No. of involved nodal sites** |              |                |               |                       |
| ≥ 3                             | 64 (30.8)    | 61 (28.9)      | 50 (35.0)     |                       |
| ≥ 4                             | 19 (9.1)     | 22 (10.4)      | 15 (10.5)     |                       |
| **GHSG criteria (n = 480)**     |              |                |               |                       |
| Favorable                       | 114 (65.1)   | 136 (73.9)     | 75 (62.0)     |                       |
| Unfavorable                     | 61 (34.9)    | 48 (26.1)      | 46 (38.0)     |                       |
| Missing                         | 33           | 27             | 22            |                       |
| **EORTC criteria (n = 492)**    |              |                |               |                       |
| Favorable                       | 118 (64.5)   | 122 (65.9)     | 68 (54.8)     |                       |
| Unfavorable                     | 65 (35.5)    | 63 (34.1)      | 56 (45.2)     |                       |
| Missing                         | 25           | 26             | 19            |                       |
| **PET score**                   |              |                |               |                       |
| 1                               | 141 (67.8)   | 157 (74.4)     | 0             |                       |
| 2                               | 67 (32.2)    | 54 (25.6)      | 0             |                       |
| 3                               | 0            | 0              | 90 (62.9)     |                       |
| 4                               | 0            | 0              | 32 (22.4)     |                       |
| 5                               | 0            | 0              | 21 (14.7)     |                       |

Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; ESR, erythrocyte sedimentation rate; GHSG, German Hodgkin Study Group; IFRT, involved-field radiotherapy; NFT, no further treatment; PET, positron emission tomography.

Baseline staging was performed by computed tomography (CT). Clinical risk stratification was retrospectively assessed according to standard criteria (Appendix Table A1, online only).

Patients received three cycles of ABVD and then underwent PET and CT assessment. Patients with progressive disease by CT criteria were excluded at this point.19 PET scans were performed within UK NCRI-accredited PET centers using standardized methods for quality control and image acquisition.20 PET images were centrally reviewed by two independent reporters at St Thomas’ Hospital, London, United Kingdom. FDG uptake was prospectively graded using a 5-point scale according to the likelihood of disease response or nonresponse. The central review score determined further management. A similar graded response method was subsequently adopted internationally, widely referred to as the Deauville criteria.15,21 A PET score of 5 was defined as 3 or more times the maximum liver uptake in RAPID, and uptake greater than the mediastinum was considered to represent a positive PET result.

In total, 602 patients were recruited between October 2003 and August 2010, of whom 571 completed three cycles of ABVD and underwent PET evaluation; 145 patients (25.4%) were PET positive (uptake ≥ mediastinum; PET score, 3, 4, or 5) and received a fourth cycle of ABVD and 30 Gy of involved-field radiotherapy (IFRT); 426 patients (74.6%) achieved complete metabolic response (CMR; PET score, 1 or 2) and were randomly assigned using a one-to-one ratio to receive 30-Gy IFRT (n = 209) or no additional treatment (NFT; n = 211). Six patients with CMR withdrew before random assignment. Three additional patients were excluded from this analysis, where review of original diagnostic material at relapse identified a non-HL diagnosis. Outcomes for 562 patients are reported here (PET positive, n = 143; IFRT, n = 208; NFT, n = 211; Fig 1). Patients were monitored for disease progression by regular clinical evaluation and by CT scans at 6, 12, and 24 months post-treatment.

Statistical Considerations

The primary end point of this subsidiary analysis was HL-specific event-free survival (EFS), calculated from the date of registration to relapse or death resulting from HL, censored at the date last seen or death resulting from any non-HL cause. PFS was calculated from the date of registration to relapse or death resulting from any cause, censored at the date last seen. Overall survival (OS) was calculated from the date of registration to death resulting from any cause, censored at the date last seen. EFS, PFS, and OS are described using the Kaplan-Meier method; univariable and multivariable Cox regression analyses were performed to explore the associations with PET score, pretreatment risk factors, and clinical prognostic scores.

RESULTS

Baseline characteristics are listed in Table 1; data for risk stratification by GHSG criteria were available for 480 patients (85.4%), of whom 155 (32.3%) had unfavorable risk. Data for stratification by EORTC criteria were available for 492 patients (87.5%), of whom 184 (37.4%) were unfavorable risk. Patients were classified as unfavorable risk
largely because of the number of involved nodal sites, age (EORTC only), and erythrocyte sedimentation rate; only one patient had extranodal disease, and patients with mediastinal bulk and B symptoms were excluded from RAPID.

After a median follow-up of 61.6 months, 44 patients (7.8%) had an HL-related event, with five deaths resulting from HL and 39 additional disease progressions. Twelve non-HL deaths occurred from pneumonia or pneumonitis related to primary HL treatment (n = 6), other malignancies (n = 4), myocardial fibrillation (n = 1), and intracranial hemorrhage (n = 1). For PET-positive patients, there was no end-of-treatment PET scan; however, no patient received salvage therapy for inadequate response in the absence of confirmed disease progression.

Outcomes by Treatment Arm

EFS was 89.7% (95% CI, 84.6% to 94.8%) at 5 years in the PET-positive group and 93.0% (95% CI, 90.5% to 95.5%) in the PET-negative group (IFRT arm: 96.0%; 95% CI, 93.1% to 98.9%; NFT arm: 90.1%; 95% CI, 85.8% to 94.4%). There was no difference in EFS between patients achieving CMR, who received three cycles of ABVD with or without IFRT, and PET-positive patients treated with four cycles of ABVD and IFRT (hazard ratio [HR], 0.68; 95% CI, 0.36 to 1.29; P = .24). There was an improvement in EFS for patients achieving CMR randomly assigned to receive IFRT compared with PET-positive patients (HR, 0.40; 95% CI, 0.17 to 0.93; P = .03) but not for those randomly assigned to receive NFT compared with PET-positive patients (HR, 0.98; 95% CI, 0.50 to 1.93; P = .95). Similar but nonsignificant results were observed for PFS.

There was better discrimination between PET-positive and -negative patients in terms of both EFS and PFS using the Lugano classification of PET positivity (PET score, 4 or 5; liver threshold) than the mediastinal threshold. Patients with a PET score of 4 or 5 had a 5-year EFS of 80.3% (95% CI, 69.3% to 91.3%).

Outcomes According to PET Score After Three Cycles of ABVD

There was strong evidence that higher PET score was associated with increased risk of progression or HL-related death (EFS; P < .001) on univariable analysis, and results remained significant, with similar effect sizes, when adjusted for baseline GHSG (P = .01) or EORTC risk stratification (P = .01). A similar association was identified between PET score and PFS (unadjusted P < .001; adjusted P = .03 and P = .04 for GHSG and EORTC stratification, respectively).

EFS and PFS by individual PET score are listed in Table 2 and Figures 2A and 2B. Patients with a score of 5 had a significantly higher risk of progression or HL-related death than those with all other PET scores (Table 3; P < .001 for both EFS and PFS). Furthermore, a score of 5 identified poor-prognosis patients among the favorable EORTC or GHSG groups, and similarly, a lower PET score identified good-prognosis patients in the unfavorable group (Appendix Figs A1A to A1D, online only). A similar association was observed for OS (P = .002; Fig 2C). The 5-year OS rate was 85.2% (95% CI, 69.7% to 100%) in patients with a score of 5, compared with 97.8% (95% CI, 96.4% to 99.2%) in patients with a score of 1 to 4. Compared with those with a score of 1 to 4, patients with a score of 5 were significantly more likely to experience an HL-related death (5-year death [EFS; P < .001] or HL-related death [P < .001]; adjusted for baseline GHSG (PET score, 4 or 5; liver threshold) than the mediastinal threshold.)

### TABLE 2. Events and 5-Year EFS and PFS Estimates According to PET Score After Three Cycles of ABVD and Pretreatment Risk Stratification

| Risk Stratum | No. of Patients | HL Relapse | HL-Related Death | Non–HL-Related Death | 5-Year EFS (%) | 5-Year PFS (%) |
|--------------|----------------|------------|-----------------|----------------------|---------------|---------------|
| PET score    |                |            |                 |                      |               |               |
| 1            | 298           | 20 (6.7)*  | 0 (0.0)         | 9 (3.0)*             | 93.4 (90.5 to 96.3) | 91.5 (88.2 to 94.8) |
| 2            | 121           | 9 (7.4)    | 1 (0.8)         | 1 (0.8)              | 91.8 (86.1 to 97.5) | 91.1 (85.2 to 97.0) |
| 3            | 90            | 3 (3.3)    | 1 (1.1)         | 0 (0.0)              | 95.3 (90.8 to 99.8) | 95.3 (90.8 to 99.8) |
| 4            | 32            | 2 (6.3)    | 0 (0.0)         | 2 (6.3)              | 93.5 (84.9 to 100) | 87.5 (76.1 to 98.9) |
| 5            | 21            | 5 (23.8)   | 3 (14.3)        | 0 (0.0)              | 61.9 (41.1 to 82.7) | 61.9 (41.1 to 82.7) |
| EORTC        |                |            |                 |                      |               |               |
| Favorable    | 308           | 25 (8.1)   | 1 (0.3)         | 1 (0.3)              | 91.7 (88.6 to 94.8) | 91.4 (88.1 to 94.7) |
| Unfavorable  | 184           | 10 (5.4)*  | 4 (2.2)         | 11 (6.0)*            | 91.4 (86.7 to 96.1) | 87.3 (82.0 to 92.6) |
| GHSG         |                |            |                 |                      |               |               |
| Favorable    | 325           | 25 (7.7)*  | 4 (1.2)         | 6 (1.8)*             | 90.8 (87.5 to 94.1) | 89.9 (86.4 to 93.4) |
| Unfavorable  | 155           | 10 (6.5)   | 1 (0.6)         | 5 (3.2)              | 92.8 (88.5 to 97.1) | 89.7 (84.8 to 94.6) |

Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; EFS, event-free survival; EORTC, European Organisation for Research and Treatment of Cancer; GHSG, German Hodgkin Study Group; HL, Hodgkin lymphoma; PET, positron emission tomography; PFS, progression-free survival.

*One patient is included in both HL relapse and non–HL-related death categories.
more likely to be male (76.2% v 53.0%; \(P = .04\)) and have 3 or more involved nodal sites (52.4% v 30.3%; \(P = .05\)), but there was a similar proportion of patients with unfavorable risk disease (Appendix Table A2, online only). Excluding patients with a PET score of 5, there was no evidence of pairwise differences between any other PET scores for EFS or PFS.

Outcomes According to Pretreatment Risk Stratification

There was no evidence of an association between baseline GHSG (HR, 1.26; 95% CI, 0.63 to 2.53; \(P = .51\)) or EORTC (HR, 1.06; 95% CI, 0.56 to 2.04; \(P = .85\)) risk group and EFS on univariable analysis (Table 3) or after adjusting for PET score (GHSG: HR, 1.31; 95% CI, 0.65 to 2.62; \(P = .45\); EORTC: HR, 1.19; 95% CI, 0.61 to 2.29; \(P = .61\)). Survival curves according to risk stratification are shown in Figures 3A and 3B. There were also no strong associations between any individual pretreatment clinical risk factors and EFS, although age was associated with PFS (Table 4), with 11 of 12 non-HL deaths occurring in patients age 50 years or older. There was no evidence of an association between baseline risk stratification and PFS, even though age

FIG 2. Kaplan-Meier curves of (A) event-free survival (EFS), (B) progression-free survival (PFS), and (C) overall survival (OS) by positron emission tomography (PET) score.
50 years or older is an unfavorable risk factor according to EORTC risk stratification.

**DISCUSSION**

The RAPID trial was a large prospective phase III randomized study and the first to our knowledge to use a graded 5-point scale for response adaptation in lymphoma, which has become the modern standard for response assessment. Contemporaneous studies used the now outdated IHP criteria, with binary positive versus negative outcomes. This subsidiary analysis from RAPID assessed the prognostic relevance of early PET, using graded response and pretreatment risk factors in early-stage HL. Our results demonstrate that PET score after three cycles of ABVD has greater prognostic value than pretreatment risk factors. These findings support the continuing use of early PET response assessment as part of risk-adapted treatment strategies for early-stage HL.

Using a binary definition of PET positivity (score, 3 to 5) did not sufficiently discriminate outcomes in RAPID. PET-positive patients had a 5-year PFS of 88.4% (95% CI, 83.1% to 93.7%), compared with 91.4% (95% CI, 88.5% to 94.3%) in those achieving CMR, although the two groups had divergent treatment strategies. Some authors have interpreted the results of RAPID and similar studies to mean that PET assessment has limited prognostic value in early-stage HL. However, the value of a positive PET scan is dependent on the threshold used. Our results demonstrate that individual PET scores are strongly associated with outcomes and reinforce the role of PET in individualized treatment planning in early-stage HL. Using the more widely accepted definition of PET positivity in the Lugano classification (score, 4 or 5) provided better discrimination, although only a score of 5 was clearly associated with adverse outcomes in RAPID.

In RAPID, patients with a PET score of 3 had excellent outcomes after ABVD and IFRT without chemotherapy intensification. With a 5-year EFS of 95.3% (95% CI, 90.8% to 99.8%) with ABVD and IFRT alone, our results do not support treatment escalation in this cohort. Whether these patients can be treated with ABVD alone remains unclear; in the PET-adapted Cancer and Leukemia Group B (CALGB) 50604 study, patients with a Deauville score of 3 had inferior outcomes to those with a score of 1 or 2 after receiving four cycles of ABVD alone, although patient numbers were small. Patients with a score of 4 also had good outcomes with ABVD and IFRT, with a 5-year EFS of 93.5% (95% CI, 84.9% to 100%), similar to patients with a score of 1 to 3. Although PFS was slightly lower in patients with a score of 4 (87.5%; 95% CI, 76.1% to 98.9%), this included two treatment-related non-HL deaths (bronchopneumonia and pneumonitis), where treatment escalation would not have been beneficial or feasible. None of the deaths in this group were attributable to HL.

Patients with a PET score of 5 after three cycles of ABVD had particularly poor outcomes, with five progressions and three HL-related deaths in only 21 patients. It is clear that treatment with ABVD and IFRT alone is inadequate for these patients, and alternative strategies should be

---

**TABLE 3.** EFS and PFS by PET Score: Unadjusted and Adjusted for Pretreatment Risk Stratification

| PET Score Comparison | EFS | PFS |
|----------------------|-----|-----|
| **Unadjusted**        |     |     |
| 5 v 1                | 6.79 (2.98 to 15.45) | < .001 | 4.79 (2.18 to 10.54) | < .001 |
| 5 v 2                | 4.96 (1.96 to 12.58) | .001 | 4.47 (1.79 to 11.11) | .001 |
| 5 v 3                | 9.43 (2.84 to 31.33) | < .001 | 9.29 (2.80 to 30.87) | < .001 |
| 5 v 4                | 6.72 (1.43 to 31.67) | .016 | 3.35 (1.01 to 11.12) | .049 |
| **Adjusted for GHSG** |     |     |
| 5 v 1                | 5.98 (2.49 to 14.36) | < .001 | 4.02 (1.74 to 9.28) | .001 |
| 5 v 2                | 4.39 (1.63 to 11.81) | .003 | 4.29 (1.60 to 11.53) | .004 |
| 5 v 3                | 7.03 (2.06 to 24.03) | .002 | 6.91 (2.02 to 23.62) | .002 |
| 5 v 4                | 4.92 (1.02 to 23.73) | .047 | 2.43 (0.71 to 8.30) | .158 |
| **Adjusted for EORTC** |     |     |
| 5 v 1                | 6.16 (2.54 to 14.91) | < .001 | 3.79 (1.63 to 8.80) | .002 |
| 5 v 2                | 4.57 (1.69 to 12.33) | .003 | 3.72 (1.41 to 9.82) | .008 |
| 5 v 3                | 7.39 (2.15 to 25.36) | .001 | 6.73 (1.96 to 23.05) | .002 |
| 5 v 4                | 5.19 (1.08 to 25.00) | .040 | 2.57 (0.75 to 8.79) | .132 |

**Abbreviations:** EFS, event-free survival; EORTC, European Organisation for Research and Treatment of Cancer; GHSG, German Hodgkin Study Group; HR, hazard ratio; PET, positron emission tomography; PFS, progression-free survival.
These might include escalation of chemotherapy intensity, as demonstrated by the H10 study,9 or introduction of novel agents.

One of the main limitations of this study is that relatively few patients had a PET score of 4, with a small number of events. Although our findings require additional confirmation, they are supported by emerging data in HL and other lymphoma subtypes that demonstrate patients with a PET score of 5 have significantly worse outcomes than those with a PET score of 4.10,24-27 Baseline PET scans were not performed; therefore, we cannot determine whether patients with a score of 5 had appearances suggestive of progressive metabolic disease, which may have a worse prognosis. However, there was no evidence of progression by CT criteria for patients in this analysis, and early progression is rare in early-stage HL.28 In other studies10,27 and international guidance,16 a score of 5 refers to uptake markedly above liver, without distinguishing whether findings also suggest disease progression, such as increasing metabolic activity and/or new lesions. There was no formal monitoring of the discrepancy rate among central PET reviewers, but several studies have demonstrated that concordance between PET readers using the 5-point scale is high (76% to 84%).8,29,30

It is unclear whether the results of the H10 study can be generalized to the RAPID population, given significant differences in inclusion criteria, particularly with respect to B symptoms and mediastinal bulk. PET scans were also performed earlier in H10, after two cycles of ABVD. However, it is notable that, although H10 was randomized, PET scans were reported only as positive or negative by IHP criteria.18 PET score was not used to stratify patients, and it is unknown whether patients with a score of 5 were balanced between treatment arms. We propose using a score of 5 as a basis for treatment escalation and/or as a stratification factor in future PET-adapted trials.

FIG 3. Kaplan-Meier curves of event-free survival (EFS) by (A) European Organisation for Research and Treatment of Cancer (EORTC) and (B) German Hodgkin Study Group (GHSG) risk group.
The PET scoring system used here and in other UK NCRI trials29 evolved directly into the 5-point Deauville scale.15 A PET score of 5 is defined as three times the maximum liver uptake in UK NCRI-led trials. The Lymphoma Study Association and Fondazione Italiana Linfomi use the lower threshold of twice the maximum liver uptake. Improvements in imaging technology, especially new reconstruction algorithms, mean that today, PET is more sensitive, and there may be a shift toward more scans being scored as 3 or 4.31 Treatment efficacy may also affect the predictive ability of PET.32 Quantitative PET(qPET), which is a ratio between residual FDG and mean liver uptake, replaces an ordinal with a continuous scale and may help to refine the threshold between adequate and inadequate response for treatment optimization and allow individualized risk estimates in the future.33,34

In RAPID, neither GHSG nor EORTC risk score was associated with outcomes. Unlike most early-stage HL studies, treatment in RAPID was not adapted according to baseline risk, and this is one of the first studies to explore the prognostic relevance of clinical risk stratification in the context of PET-adapted treatment. Given the much stronger association with PET score, our findings suggest that pretreatment risk stratification may have diminished relevance with PET-adapted treatment, particularly for patients without mediastinal bulk or B symptoms. It is unclear whether our findings are applicable to the wider early-stage HL population, particularly patients with mediastinal bulk, who were excluded from RAPID and in whom the association with adverse outcomes may be stronger.6 However, all risk factors are weighted equally within EORTC and GHSG groupings, which are designed to apply to all patients with early-stage HL, including the RAPID population; therefore, our findings highlight weaknesses in current risk stratification models.

Our results are similar to those of retrospective studies in advanced-stage HL, where the International Prognostic Score failed to retain independent prognostic significance over interim PET assessment.7,35 Indeed, in a subsidiary analysis of H10, only PET assessment, but not baseline risk stratification, was prognostic on multivariable analysis, although treatment was adapted according to EORTC stratification.28 A subsidiary analysis of the GHSG early-stage HL trials in the pre-PET era showed a small absolute difference in PFS between favorable and unfavorable risk groups for patients treated with ABVD and IFRT (9.4% for GHSG and 6.7% for EORTC risk stratification).6 These findings emphasize the need to re-evaluate the use of clinical prognostic grouping in early-stage HL in the era of PET-adapted therapy. Incorporation of biological or baseline PET parameters may be required to improve pretreatment risk stratification.28,36,37

In conclusion, this subsidiary analysis of the RAPID trial demonstrates that PET response assessment after chemotherapy has a much stronger association with outcomes than clinical risk stratification in early-stage HL. We have shown that a positive PET scan does not carry uniform prognostic weight, with only a PET score of 5 associated with inferior outcomes in RAPID; patients with nonbulky early-stage HL and a PET score of 3 or 4 after three cycles of ABVD were treated effectively with a fourth cycle of ABVD and IFRT. In future trials, we propose reserving treatment escalation with its attendant toxicity in this patient group for those with a PET score of 5, who have significantly worse outcomes than those patients with PET scores of 1 to 4. These results support the continued development and use of PET-adapted strategies in early-stage HL.
REFERENCES

1. Meyer RM, Gospodarowicz MK, Connors JM, et al: ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366: 399-408, 2012
2. Schaapveld M, Aleman BM, van Eggermond AM, et al: Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med 373: 2499-2511, 2015
3. Raemaekers JMM, Andre MPE, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014
4. Behringer K, Goergen H, Hitz F, et al: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial. Lancet 385:1418-1427, 2015
5. von Treisckow B, Plutschow A, Fuchs M, et al: Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:907-913, 2012
6. Klimm B, Goergen H, Fuchs M, et al: Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: An analysis of international staging definitions. Ann Oncol 24:3070-3076, 2013
7. Gallamini A, Barrington SF, Biggi A, et al: The predictive role of interim positron emission tomography in Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99:1107-1113, 2014
8. Biggi A, Gallamini A, Chauvie S, et al: International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med 54:683-690, 2013
9. André MPE, Grinisky T, Federico M, et al: Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35:1786-1794, 2017
10. Johnson P, Federico M, Kirkwood A, et al: Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 374:2419-2429, 2016
11. Radford J, Illidge T, Counsell N, et al: Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 372:1598-1607, 2015
12. Strauss DJ, Jung SH, Pitcher B, et al: CALGB 50604: Risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132: 1013-1021, 2018
13. Fuchs M, Goergen H, Kobe C, et al: PET-guided treatment of early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase 3 trial HD16 by the German Hodgkin Study Group. Blood 132, 2018 pp 925-933
14. Hoppe RT, Advani RH, Ai WZ, et al: Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:608-638, 2017
15. Meignan M, Gallamini A, Meignan M, et al: Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257-1260, 2009
16. Barrington SF, Mikhaeel NG, Kostakoglu L, et al: Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048-3058, 2014
17. Maraldo MV: Continued conundrum of PET-CT and Hodgkin's lymphoma. J Clin Oncol 22:739-745, 2011
18. Chenoweth BR, Habeck ML, Castrillon DH, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17: 1244, 1999
19. Barrington SF, Mackewin JE, Schleyer P, et al: Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol 22:739-745, 2011
20. Chenoweth BR, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3067, 2014
21. Adkins N, Keen TC: The predictive value of interim FDG-PET in early-stage Hodgkin lymphoma is not well established. Ann Oncol 29:510-512, 2018
22. Coyle M, Kostakoglu L, Evens AM: The evolving role of response-adapted PET imaging in Hodgkin lymphoma. Ther Adv Hematol 7:108-125, 2016
23. Cerami L, Martelli M, Gospodarowicz MK, et al: Positron emission tomographycomputed tomography assessment after immunocombination therapy and irradiation using the Lugano classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma. Int J Radiat Oncol Biol Phys 97:42-49, 2017
24. Hertzberg M, Gandhi MK, Trotman J, et al: Early treatment intensification with R-ICE and 90Y-ibritumomab tuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica 102:356-363, 2017
26. Mikhaeel GN, Brady J, McMillan A, et al: Blinded evaluation of the prognostic value of FDG-PET after 2 cycles of R-CHOP in DLBCL UK-NCRI study. Hematol Oncol 33, 2015 (abstr 258a)
27. Melani C, Advani R, Roschewski M, et al: End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: A paradigm shift in clinical decision making. Haematologica 103:1337-1344, 2018
28. Cottereau AS, Versari A, Loft A, et al: Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131:1456-1463, 2018
29. Barrington SF, Kirkwood AA, Franceschetto A, et al: PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 127:1531-1538, 2016
30. Barrington SF, Qian W, Somer EJ, et al: Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824-1833, 2010
31. Boellaard R, Kobe C, Zijlstra JM, et al: Does PET reconstruction method affect Deauville scoring in lymphoma patients? J Nucl Med 59:1167-1169, 2018
32. Johnson P, Longley J: Should response-adapted therapy now be the standard of care for advanced Hodgkin's lymphoma? Curr Treat Options Oncol 18:15, 2017
33. Hasenclever D, Kurch L, Mauz-Körholz C, et al: qPET: A quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging 41:1301-1308, 2014
34. Barrington SF, Kluge R: FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 44:97-110, 2017 (suppl 1)
35. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
36. Pike LC, Kirkwood AA, Patrick P, et al: Can baseline PET-CT features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033). Hematol Oncol 35:37-38, 2017
37. Mottok A, Steidl C: Biology of classical Hodgkin lymphoma: Implications for prognosis and novel therapies. Blood 131:1654-1665, 2018

---

Order ASCO Answers Fact Sheets for Your Office or Waiting Room

ASCO Answers fact sheets provide an introduction to more than 60 types of cancer and cancer topics, including treatments and side effects. Download fact sheets at cancer.net/ascoanswers or order them for your practice through the ASCO University Bookstore at cancer.net/estore. Free domestic shipping on all patient information resources and ASCO members save 20%.

Cancer.Net
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org/jco/site/ifc.

Sally F. Barrington
Speakers' Bureau: F. Hofmann-La Roche
Research Funding: Bristol-Myers Squibb (Inst), Celgene (Inst), F. Hofmann-La Roche (Inst), Angen (Inst)

Elizabeth H. Phillips
Research Funding: F. Hoffmann-La Roche (Inst)

Ruth Pettengell
Honoraria: CTI Life Sciences, Immune Design, Pfizer, Roche/Genentech, Servier, Takeda Pharmaceuticals, TEVA Pharmaceuticals Industries
Travel, Accommodations, Expenses: Takeda Pharmaceuticals, Pfizer, Servier

Peter Johnson
Honoraria: Takeda Pharmaceuticals, Bristol-Myers Squibb, Novartis, Celgene, Kite Pharma, Genmab, Incyte, MorphoSys
Consulting or Advisory Role: Janssen, Epizyme, Boehringer Ingelheim
Research Funding: Epizyme (Inst), Janssen (Inst)
Patents, Royalties, Other Intellectual Property: Combined use of Fc gamma RIIb (CD32b) – and CD20-specific antibodies, WO patent, PCT/GB2011/051572; EU11760819.0

William Townsend
Consulting or Advisory Role: Roche
Travel, Accommodations, Expenses: Roche

Dominic Culligan
Honoraria: AbbVie, Pfizer, Takeda Pharmaceuticals, Daiichi Sankyo, Merck Sharp & Dohme, Jazz Pharmaceuticals
Consulting or Advisory Role: AbbVie, Daiichi Sankyo, Pfizer, Takeda Pharmaceuticals, Merck Sharp & Dohme, Jazz Pharmaceuticals
Speakers' Bureau: Takeda Pharmaceuticals, Celgene
Travel, Accommodations, Expenses: AbbVie, Celgene/Jazz Pharmaceuticals, Daiichi Sankyo

Laura Clifton-Hadley
Research Funding: Pfizer (Inst), Bristol-Myers Squibb (Inst), Takeda Pharmaceuticals (Inst), Janssen (Inst)

Andrew McMillan
Honoraria: Roche/Genentech, Celgene, Bristol-Myers Squibb, MSD Oncology, Novartis
Consulting or Advisory Role: Celgene (I)
Speakers' Bureau: Roche/Genentech
Research Funding: Pfizer, Roche/Genentech (Inst)
Travel, Accommodations, Expenses: Roche/Genentech, Celgene, Takeda Pharmaceuticals

Peter Hoskin
Research Funding: Varian Medical Systems (Inst), Astellas Pharma (Inst), Bayer HealthCare Pharmaceuticals (Inst)
Travel, Accommodations, Expenses: Elekta

Tim Illidge
Consulting or Advisory Role: Takeda Pharmaceuticals, Nordic Nanovector
Speakers' Bureau: Takeda Pharmaceuticals, Bristol-Myers Squibb, Roche
Research Funding: AstraZeneca/MedImmune, MSD Oncology
Travel, Accommodations, Expenses: Roche

John Radford
Stock and Other Ownership Interests: GlaxoSmithKline (I), AstraZeneca (I)
Honoraria: Takeda Pharmaceuticals
Consulting or Advisory Role: Takeda Pharmaceuticals, Seattle Genetics, Novartis
Speakers' Bureau: Takeda Pharmaceuticals, Seattle Genetics, Novartis
Research Funding: Takeda Pharmaceuticals
Travel, Accommodations, Expenses: Takeda Pharmaceuticals
Travel, Accommodations, Expenses: ADC Therapeutics

No other potential conflicts of interest were reported.
FIG A1. Kaplan-Meier curves of event-free survival (EFS) by positron emission tomography score (PET) of 1 to 4 versus 5 for (A) EORTC favorable risk, (B) EORTC unfavorable risk, (C) GHSG favorable risk, and (D) GHSG unfavorable risk.
### TABLE A1. Pretreatment Risk Stratification in Early-Stage HL

| Criterion                          | GHSG   | EORTC  |
|------------------------------------|--------|--------|
| ESR                                |        |        |
| B symptoms                         | ≥ 30   | ≥ 30   |
| No B symptoms                      | ≥ 50   | ≥ 50   |
| No. of involved nodal areas        | ≥ 3*   | ≥ 4†   |
| Extranodal disease                 | Present|        |
| Age, years                         |        | ≥ 50   |
| Mediastinal mass                   | ≥ One third maximum thoracic diameter‡ | Mediastinum-to-thorax ratio ≥ 0.35 |

*Note. Patients with stage I or II Hodgkin lymphoma (HL) are classified as having unfavorable risk disease if any one of these adverse risk factors listed is present.

Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; ESR, erythrocyte sedimentation rate; GHSG, German Hodgkin Study Group.

* Of 11 GHSG nodal areas.
† Of five supradiaphragmatic EORTC nodal areas.
‡ Patients with stage IIB disease and mediastinal mass and/or extranodal disease are treated as having advanced-stage disease by GHSG criteria.
### TABLE A2. Baseline Demographic and Clinical Characteristics by PET Group (N = 562)

| Characteristic                  | 1 to 4 (n = 541) | 5 (n = 21) | Total (N = 562) | P  |
|---------------------------------|------------------|------------|-----------------|----|
| **PET Score**                   |                  |            |                 |    |
| Age, years                      |                  |            |                 |    |
| Median                          | 34               | 34         | 34              | .53|
| Range                           | 16-75            | 18-74      | 16-75           |    |
| Age, years < 50                 | 416 (76.9)       | 13 (61.9)  | 429 (76.3)      |    |
| Age, years ≥ 50                 | 125 (23.1)       | 8 (38.1)   | 133 (23.7)      |    |
| Sex                             |                  |            |                 | .04|
| Female                          | 254 (47.0)       | 5 (23.8)   | 259 (46.1)      |    |
| Male                            | 287 (53.0)       | 16 (76.2)  | 303 (53.9)      |    |
| Stage                           |                  |            |                 | .48|
| IA                              | 180 (33.3)       | 5 (23.8)   | 185 (32.9)      |    |
| IIA                             | 361 (66.7)       | 16 (76.2)  | 377 (67.1)      |    |
| ESR ≥ 50 (n = 468)              | 60 (13.4)        | 1 (5.3)    | 61 (13.0)       | .49|
| Nonmediastinal bulk present     | 6 (1.1)          | 0          | 6 (1.1)         |    |
| Extranodal disease present      | 1 (0.2)          | 0          | 1 (0.2)         |    |
| No. of involved nodal sites     |                  |            |                 | .05|
| ≥ 3                             | 164 (30.3)       | 11 (52.4)  | 175 (31.1)      |    |
| ≥ 4                             | 53 (9.8)         | 3 (14.3)   | 56 (10.0)       | .46|
| GHSG criteria (n = 480)         |                  |            |                 | .81|
| Favorable                       | 312 (67.8)       | 13 (65.0)  | 325 (67.7)      |    |
| Unfavorable                     | 148 (32.2)       | 7 (35.0)   | 155 (32.3)      |    |
| Missing                         | 81               | 1          | 82              |    |
| EORTC criteria (n = 492)        |                  |            |                 | .25|
| Favorable                       | 298 (63.1)       | 10 (50.0)  | 308 (62.6)      |    |
| Unfavorable                     | 174 (36.9)       | 10 (50.0)  | 184 (37.4)      |    |
| Missing                         | 69               | 1          | 70              |    |

Abbreviations: ESR, erythrocyte sedimentation rate; EORTC, European Organisation for Research and Treatment of Cancer; GHSG, German Hodgkin Study Group; PET, positron emission tomography.